DRG Epidemiology’s coverage of HIV/AIDS-related neuropathy comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of HIV/AIDS-related neuropathy for each country, as well as annualized case counts projected to the national population.

DRG Epidemiology’s HIV/AIDS-related neuropathy forecast will answer the following questions:

  • Of all people with HIV/AIDS-related neuropathy, how many in each major mature pharmaceutical market experience NP?
  • Of all people with HIV/AIDS-related NP, how many in each major mature pharmaceutical market have been formally diagnosed?
  • Of all people diagnosed with HIV/AIDS-related NP, how many in each major mature pharmaceutical market are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of HIV/AIDS-related neuropathy over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.

In addition to the total number of cases for each forecast year, DRG Epidemiology provides at least ten years of forecast data for the following HIV/AIDS-related neuropathy subpopulations:

  • Total prevalent cases of HIV/AIDS-related NP.
  • Diagnosed prevalent cases of HIV/AIDS-related NP.
  • Drug-treated prevalent cases of HIV/AIDS-related NP.

Note: Coverage may vary by country.

Table of contents

  • HIV/AIDS-Related Neuropathy - Epidemiology - Mature Markets Data

Author(s): Sunali D. Goonesekera, SM

Sunali Goonesekera is an Associate Epidemiologist at Decision Resources Group.

Sunali holds a Master’s degree in Epidemiology from the Harvard School of Public Health and a B.A. in Biology (Honors) from Dartmouth College. Prior to joining Decision Resources Group, Sunali conducted epidemiological research and lead authored two manuscripts on racial/ethnic disparities in metabolic diseases at the New England Research Institutes. She has contributed to multiple publications in peer-reviewed journals in epidemiology and in the biological sciences.

Related Reports

Neuropathic Pain - Landscape & Forecast - Disease Landscape & Forecast

The treatment of neuropathic pain involves the use of drugs from several drug classes, including antidepressants, antiepileptic drugs, local anesthetics, dual-acting opioid analgesics, and opioid a...

View Details

Neuropathic Back Pain - Epidemiology - Extrapolated Worldwide Coverage

DRG’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key neuropathic back pa...

View Details